Abstract: The invention relates to Nucleobindin-1 (NUCB1) protein variants that are capable of disaggregating amyloid fibrils as well as inhibiting the formation of fibrils in the presence of physiological concentrations of calcium. Isolated NUCB1 protein variants, nucleic acids encoding the protein variants, cells comprising the isolated nucleic acids, pharmaceutical compositions and kits comprising the variants, methods of making the variants, and therapeutic uses of the variants are provided.
Type:
Application
Filed:
July 16, 2009
Publication date:
September 15, 2011
Applicants:
The Rockerfeller University, THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
Inventors:
Thomas P. Sakmar, Santosh T. Menon, Neeraj Kapoor, Ruchi Gupta, Dan Raleigh
Abstract: The present invention provides a unique src-family kinase (SFK) that plays a key role in the transformation of early-stage embryonic cells to mesodermal cells. Furthermore, this src-family kinase is likely to be a proto-oncogene. The nucleic acid and amino acid sequences are disclosed.
Type:
Grant
Filed:
January 12, 1999
Date of Patent:
September 18, 2001
Assignee:
The Rockerfeller University
Inventors:
Ali Hemmait-Brivanlou, Daniel C. Weinstein
Abstract: A detailed three-dimensional structure for the complex formed between Ras and the Son of sevenless (Sos) protein is provided. Crystals of this complex are also included in the invention. The present invention farther provides procedures for identifying agents that can inhibit tumor proliferation through the use of rational drug design predicated on the crystals and crystallographic data disclosed.
Type:
Grant
Filed:
July 21, 1998
Date of Patent:
December 5, 2000
Assignees:
The Rockerfeller University, The Research Foundation of State University of New York
Inventors:
Ann Boriack-Sjodin, S. Mariana Margarit, Dafna Bar-Sagi, Philip Cole, John Kuriyan